Life Science Engineering Consultant
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree!!
I had 80-90% buys on my Schwab chart data.
Uodate: From the FDA Website 4/28
Q: What serology tests are being offered under the policy outlined in Section IV.D of the Policy for Diagnostic Tests for Coronavirus Disease-2019? (Updated 4/28)
A: As stated in Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019, the FDA does not intend to object to the development and distribution by commercial manufacturers, or development and use by laboratories, of serology tests to identify antibodies to SARS-CoV-2, where the test has been validated, notification is provided to FDA, and information along the lines of the following is included in the test reports:
This test has not been reviewed by the FDA.Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
To help ensure the above information is provided in the test report, as described in the guidance, commercial manufacturers could include this information in their Instructions for Use (IFU) or other labeling provided to laboratories.
This policy does not apply to at home testing.
The commercial manufacturers and laboratories in the two lists below have notified FDA that they have validated and are offering serology tests as set forth in Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019. Unless an Emergency Use Authorization (EUA) has also been submitted and reviewed, the FDA has not reviewed the validation of tests offered by these developers, who may not be pursuing EUAs. FDA is including this list here to provide transparency regarding the notifications submitted to FDA.
Laboratories that have notified FDA that they have validated and are offering serology tests as set forth in Section IV.D:
Where the Authorization Status is "FDA Authorized," the FDA reviewed and issued an EUA for the test after notification was given. Where the Authorization Status is shown as "Not FDA Authorized," the FDA has not yet reviewed the laboratory's validation and issued an EUA for the laboratory's test, and the test is included in this list to provide transparency regarding the notifications submitted to FDA. The "Setting for Use" designation of "H" refers to a laboratory certified under CLIA to perform high-complexity testing.
Search:
LaboratoryAuthorization StatusSettings for Use
1Access Medical Laboratories Not FDA AuthorizedH
Arrayit CorporationNot FDA AuthorizedH
Beaumont HealthNot FDA AuthorizedH
BioDiagnostic Inc.Not FDA AuthorizedH
Bioreference Laboratories Inc.Not FDA AuthorizedH
Boston Heart DiagnosticsNot FDA AuthorizedH
Dept of Pathology & Laboratory Medicine @ The Medical Center, Navicent HealthNot FDA AuthorizedH
DLS Research & VenturesNot FDA AuthorizedH
EDP Biotech CorporationNot FDA AuthorizedH
Emory Medical LaboratoriesNot FDA AuthorizedH
HealthQuest EsotericsNot FDA AuthorizedH
IMMYLabsNot FDA AuthorizedH
Lenco Diagnostic LaboratoryNot FDA AuthorizedH
Mayo ClinicNot FDA AuthorizedH
Michigan Health ClinicsNot FDA AuthorizedH
National Jewish HealthNot FDA AuthorizedH
OtogeneticsNot FDA AuthorizedH
Progenesis, Inc.Not FDA AuthorizedH
Rady Children's Hospital - San DiegoNot FDA AuthorizedH
Roseland Community Hospital/American Medical LabNot FDA AuthorizedH
University of Minnesota Advanced Research and Diagnostic LaboratoryNot FDA AuthorizedH
US Specialty LabsNot FDA AuthorizedH
Vibrant America Clinical LabsNot FDA AuthorizedH
VRL EurofinsNot FDA AuthorizedH
They are on the list for potential Authorization of their Serology Test.
Read this: Arrayit Update 4/20/2020
Q: What serology tests are being offered under the policy outlined in Section IV.D of the Policy for Diagnostic Tests for Coronavirus Disease-2019? (Updated 4/20)
A: As stated in Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019, the FDA does not intend to object to the development and distribution by commercial manufacturers, or development and use by laboratories, of serology tests to identify antibodies to SARS-CoV-2, where the test has been validated, notification is provided to FDA, and information along the lines of the following is included in the test reports: This test has not been reviewed by the FDA.Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
To help ensure the above information is provided in the test report, as described in the guidance, commercial manufacturers could include this information in their Instructions for Use (IFU) or other labeling provided to laboratories. This policy does not apply to at home testing. The commercial manufacturers and laboratories in the two lists below have notified FDA that they have validated and are offering serology tests as set forth in Section IV.D of the FDA's Policy for Diagnostic Tests for Coronavirus Disease-2019. Unless an Emergency Use Authorization (EUA) has also been submitted and reviewed, the FDA has not reviewed the validation of tests offered by these developers, who may not be pursuing EUAs. FDA is including this list here to provide transparency regarding the notifications submitted to FDA.
Laboratories that have notified FDA that they have validated and are offering serology tests as set forth in Section IV.D: Where the Authorization Status is "FDA Authorized," the FDA reviewed and issued an EUA for the test after notification was given. Where the Authorization Status is shown as "Not FDA Authorized," the FDA has not yet reviewed the laboratory's validation and issued an EUA for the laboratory's test, and the test is included in this list to provide transparency regarding the notifications submitted to FDA. The "Setting for Use" designation of "H" refers to a laboratory certified under CLIA to perform high-complexity testing. Search: LaboratoryAuthorization Status Settings for Use
Arrayit Corporation Not FDA Authorized H
Beaumont Health Not FDA Authorized H
Bioreference Laboratories Inc.Not FDA Authorized H
Boston Heart Diagnostics Not FDA Authorized H
DLS Research & Ventures Not FDA Authorized H
EDP Biotech Corporation Not FDA Authorized H
Emory Medical Laboratories Not FDA Authorized H
IMMYLabs Not FDA Authorized H
Lenco Diagnostic Laboratory Not FDA Authorized H
Mayo Clinic Not FDA Authorized H
Michigan Health Clinics Not FDA Authorized H
Otogenetics Not FDA Authorized H
Roseland Community Hospital/American Medical Lab Not FDA Authorized H
University of Minnesota Advanced Research and Diagnostic Laboratory Not FDA Authorized H
Vibrant America Clinical Labs Not FDA Authorized H
Showing 1 to 15 of 15 entries 1 Settings for use include the following: H - Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
Spot on Mike!!
4/20 UPDATE!!
Partially copied from FDA Website:
Q: What serology tests are being offered under the policy outlined in Section IV.D of the Policy for Diagnostic Tests for Coronavirus Disease-2019? (Updated 4/20)
Arrayit Corporation Not FDA Authorized H
Beaumont Health Not FDA Authorized H
Bioreference Laboratories Inc.Not FDA Authorized H
Boston Heart Diagnostics Not FDA Authorized H
DLS Research & Ventures Not FDA Authorized H
EDP Biotech Corporation Not FDA Authorized H
Emory Medical Laboratories Not FDA Authorized H
IMMYLabs Not FDA Authorized H
Lenco Diagnostic Laboratory Not FDA Authorized H
Mayo Clinic Not FDA Authorized H
Michigan Health Clinics Not FDA Authorized H
Otogenetics Not FDA Authorized H
Roseland Community Hospital/American Medical Lab Not FDA Authorized H
University of Minnesota Advanced Research and Diagnostic Laboratory Not FDA Authorized H
Vibrant America Clinical Labs Not FDA Authorized H
Showing 1 to 15 of 15 entries 1 Settings for use include the following: H - Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.
"CEO Rene Schena states, “We are pleased that a major pharmacy retailer continues to evaluate our finger stick allergy testing services for in-store sale at their retail pharmacies and health clinics.”
The sheep are lead to sell by the shorters.
I know the science. R&D 16 yrs. with Corning Life Science. Thid technology is the future. Enough said..
Auditor for Arrayit worked for SEC. I don't think he would let that happen.
Please Read. This will pass sooner than you think. This is your opportunity to buy in. I had a feeling this would happen but it will rebound to new heights, guaranteed.
Please Read. This will pass sooner than you think. This is your opportunity to buy in. I had a feeling this would happen but it will rebound to new heights, guaranteed.
Please Read. This will pass sooner than you think. This is your opportunity to buy in. I had a feeling this would happen but it will rebound to new heights, guaranteed.
Perhaps to include this revenue and publish 1st quarter results?
Jan.1-Mar. 31.
The Finance Team is hurrying to gather up the remaining revenue from
Repost: Most Current top 10 Key Players in the Worldwide Microarray Market. We are in extremely good company.
https://ashutosh213.wordpress.com/2019/03/14/microarray-analysis-market-worldwide-research-trends-and-development-of-2023/
Here is the most current list:
Key Players of Microarrays Analysis:
QIAGEN (Germany), Merck Sharp & Dohme Corp (US), Bio-Rad Laboratories, Inc. (US), Applied Micro Arrays (US), Agilent Technologies (US), Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), PerkinElmer Inc. (US), Arrayit Corporation (US), BioGenex (US), and General Electric Company (UK)
Arrayit currently ranked with the top 10 Key Players in the Worldwide Microarray Market.
Arrayit is on an irreversible trend to the top of the world Microarray Market.
https://ashutosh213.wordpress.com/2019/03/14/microarray-analysis-market-worldwide-research-trends-and-development-of-2023/
This Bird can talk...
WELL DONE!! This is how DD should be done. Nice Job!
"KEY MARKET PLAYERS"
Key Players
Among many layers, some of the key player in the market are QIAGEN
(Germany), Thermo Fisher Scientific, Inc. (US), Agilent Technologies (US),
Applied Micro Arrays (US), Merck Sharp & Dohme Corp (US), Bio-Rad
Laboratories, Inc. (US), PerkinElmer Inc. (US), Illumina, Inc. (US), Arrayit
Corporation (US), BioGenex (US) and General Electric Company (UK).
Market A
More good news!!
Apple follows Amazon into health care
Apple is opening health clinics for employees and their families, CNBC reports. The program, called AC Wellness, will kick off in the spring. “The iPhone maker has been typically secretive about its plans,” writes the Financial Times, but CEO Tim Cook recently told shareholders that Apple could make a “significant contribution” to the health care industry. The news comes after a similar move from Amazon, Berkshire Hathaway and JPMorgan Chase, which recently announced a joint health care initiative for their employees.
ARYC...Always recognized as a key player.
http://www.abnewswire.com/pressreleases/world-tissue-microarray-market-is-projected-to-reach-at-a-cagr-1088-by-2023_163502.html
Per my previous post:
The leading players in the market for microarray instruments are Affymetrix, Inc., Illumina, Inc., Agilent Technologies, Molecular Devices, ArrayIt Corporation, ThermoFischer Scientific and others which include Bio-Rad Laboratories, ArrayJet, and Sigma Aldrich. Greater benefits are expected to be achieved by various companies with huge investments in automation of systems with improved analysis in the near future.
Arrayit Market Confirmation
http://www.prnewswire.com/news-releases/dna-microarray-market-1516-cagr-to-2020-597272311.html
Try searching John Commissiong WO2011038366
These two won't be shorting anymore...
http://www.sec.gov/News/PressRelease/Detail/PressRelease/1370540710839#.UxINu-NdUlk
Very well said Risk...Gerald has the resolve to build his Field of Dreams. Listen to his opening remarks at C4CT...his exudes confidence in his opening statement to this group of experts.
http://webtv.un.org/search/opening-remarks-concussion-awareness-summit/3123201347001?term=C4CT
Dr.Jerry...Would compounding eltoprazine with MANF require toxicology testing on MANF separately and in combination with before moving forward into clinical trials?
Zoom...Thanks for filling in the rest of the story!
You're correct Zoom! It has been MJJF funded from 2008 to present:
https://www.michaeljfox.org/foundation/funded-grants.php
Eltoprazine on going work done @MJJF by Dr. Carta awaiting outcome.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1126